Search results
Showing 721 to 735 of 1962 results for nice guidelines
Evidence-based recommendations on imatinib for treating unresectable or metastatic gastrointestinal stromal tumours in adults.
Transcutaneous electrical neuromuscular stimulation for urinary incontinence (HTG636)
Evidence-based recommendations on transcutaneous electrical neuromuscular stimulation for urinary incontinence in adults. This involves stimulating nerves and muscles in the pelvic floor to strengthen the muscles and reduce urine leaks.
View recommendations for HTG636Show all sections
Summary of the evidence on flunarizine for treating migraine prophylaxis to inform local NHS planning and decision-making
We work with the clinical classifications service of NHS Digital to provide relevant clinical coding information for interventional procedure and medical technologies guidance.
Biomarker tests to help diagnose preterm labour in women with intact membranes (HTG476)
Evidence-based recommendations on biomarker tests to help diagnose preterm labour in women with intact membranes. The tests are Actim Partus, PartoSure and the Rapid fetal fibronectin (fFN) 10Q Cassette Kit (at thresholds other than 50 nanograms/millilitre).
Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults.
Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making
Our Medical Technologies Evaluation Programme (MTEP) evaluates new HealthTech.
Focal therapy using high-intensity focused ultrasound for localised prostate cancer (HTG667)
Evidence-based recommendations on focal therapy using high-intensity focused ultrasound for localised prostate cancer. This involves using high-intensity focused ultrasound to heat up and destroy only the areas of the prostate with cancer (focal therapy). The aim is to destroy the cancer while reducing damage to healthy prostate tissue.
View recommendations for HTG667Show all sections
Evidence-based recommendations on sacubitril valsartan (Entresto) for treating symptomatic chronic heart failure with reduced ejection fraction.
Type 2 diabetes: insulin degludec/liraglutide (Xultophy) (ESNM60)
Summary of the evidence on insulin degludec/liraglutide (Xultophy) for treating type 2 diabetes to inform local NHS planning and decision-making
This indicator covers the percentage of patients with dementia (diagnosed on or after 1 April 2014) with a record of FBC, calcium, glucose, renal and liver function, thyroid function tests, serum vitamin B12 and folate levels recorded up to 12 months before entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM72
Evidence-based recommendations on bulevirtide (Hepcludex) for chronic hepatitis D in adults.
We want you to be involved in our work - whether you’re commenting on our draft recommendations, taking part in guidance development or attending a committee meeting, your voice is important to us.
Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)
Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with reduced ejection fraction in adults.